Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDL NASDAQ:GOVX NASDAQ:VUZI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.22-4.7%$1.32$0.88▼$1.71$136.42M0.77360,609 shs335,446 shsGOVXGeoVax Labs$2.06-14.2%$1.60$0.96▼$34.75$7.15M3.3614.84 million shs1.11 million shsVUZIVuzix$4.60+2.2%$2.95$1.83▼$5.62$382.53M1.522.68 million shs4.35 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics-4.69%-7.58%-6.87%+19.61%-4.69%GOVXGeoVax Labs-14.17%-43.41%+96.19%+28.75%-92.23%VUZIVuzix+2.22%-10.51%+93.28%+59.17%+69.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.22-4.7%$1.32$0.88▼$1.71$136.42M0.77360,609 shs335,446 shsGOVXGeoVax Labs$2.06-14.2%$1.60$0.96▼$34.75$7.15M3.3614.84 million shs1.11 million shsVUZIVuzix$4.60+2.2%$2.95$1.83▼$5.62$382.53M1.522.68 million shs4.35 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics-4.69%-7.58%-6.87%+19.61%-4.69%GOVXGeoVax Labs-14.17%-43.41%+96.19%+28.75%-92.23%VUZIVuzix+2.22%-10.51%+93.28%+59.17%+69.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 2.33Hold$8.50596.72% UpsideGOVXGeoVax Labs 1.50Reduce$150.007,181.55% UpsideVUZIVuzix 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest VUZI, GOVX, and CRDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026GOVXGeoVax Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026VUZIVuzix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026GOVXGeoVax Labs D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold4/6/2026CRDLCardiol Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.00(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.16 per shareN/AGOVXGeoVax Labs$2.49M2.87N/AN/A$0.14 per share14.71VUZIVuzix$6.28M60.91N/AN/A$0.29 per share15.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)GOVXGeoVax Labs-$21.47M-$19.12N/AN/AN/AN/A-709.52%-399.33%7/27/2026 (Estimated)VUZIVuzix-$32.27M-$0.40N/AN/AN/A-504.12%-116.50%-77.83%8/13/2026 (Estimated)Latest VUZI, GOVX, and CRDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q4 2025GOVXGeoVax Labs-$3.8421-$2.62+$1.2221-$2.62N/AN/A5/14/2026Q1 2026VUZIVuzix-$0.10-$0.09+$0.01-$0.09$1.35 million$1.39 million5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/A4/15/2026Q4 2025GOVXGeoVax LabsN/A$1.85N/A$1.85N/AN/A3/30/2026Q4 2025CRDLCardiol Therapeutics-$0.09-$0.05+$0.04-$0.05N/AN/A3/12/2026Q4 2025VUZIVuzix-$0.09-$0.12-$0.03-$0.12$1.92 million$2.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AGOVXGeoVax LabsN/AN/AN/AN/AN/AVUZIVuzixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol TherapeuticsN/A4.394.39GOVXGeoVax LabsN/A1.061.06VUZIVuzixN/A6.195.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%GOVXGeoVax Labs6.09%VUZIVuzix35.87%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%GOVXGeoVax Labs0.57%VUZIVuzix7.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics20111.82 million105.95 millionNot OptionableGOVXGeoVax Labs103.47 million3.45 millionNot OptionableVUZIVuzix11083.16 million77.09 millionOptionableVUZI, GOVX, and CRDL HeadlinesRecent News About These CompaniesPaula Beck Whitten-Doolin Sells 32,000 Shares of Vuzix (NASDAQ:VUZI) StockMay 28 at 6:41 AM | insidertrades.comVuzix (NASDAQ:VUZI) Upgraded by Wall Street Zen to Hold RatingMay 24, 2026 | americanbankingnews.comIs Vuzix (VUZI) Quietly Redefining Its Defense Edge With New Covert AR Waveguide Tech?May 22, 2026 | finance.yahoo.comInsider Selling: Vuzix (NASDAQ:VUZI) Director Sells $47,300.00 in StockMay 22, 2026 | insidertrades.comNasdaq AR Penny Stocks Gaining Fresh Market BuzzMay 21, 2026 | kalkinemedia.comKVuzix Earnings Call Balances Growth Plans and StrainMay 20, 2026 | tipranks.comVuzix Showcasing Advanced Waveguide Solutions for Defense and Tactical Operations During SOF Week 2026May 19, 2026 | prnewswire.comVuzix stock sank despite Q1 beatsMay 16, 2026 | fool.comVuzix earnings call: pipeline builds, cash burnsMay 15, 2026 | tipranks.comWhy Vuzix Corporation’s (VUZI) Stock Is Down 15.75%May 15, 2026 | aaii.comAVuzix (VUZI) Q1 2026 Earnings TranscriptMay 15, 2026 | fool.comVuzix Corp (VUZI) Q1 2026 Earnings Call Highlights: Strategic Defense Contracts and Smart ...May 15, 2026 | finance.yahoo.comVuzix Q1 Earnings Call HighlightsMay 15, 2026 | marketbeat.comVuzix Q1 earnings previewMay 14, 2026 | msn.comTop augmented reality companies to watch in 2026May 14, 2026 | msn.comVuzix: Q1 Earnings SnapshotMay 14, 2026 | chron.comVuzix Corporation (VUZI) Q1 2026 Earnings Call Prepared Remarks TranscriptMay 14, 2026 | seekingalpha.comVuzix Reports First Quarter 2026 ResultsMay 14, 2026 | prnewswire.comVuzix (VUZI) Lands Another Defense Contract As Military Demand Continues To GrowMay 14, 2026 | insidermonkey.comMitsubishi UFJ Asset Management Co. Ltd. Acquires 848,142 Shares of Vuzix Corporation $VUZIMay 11, 2026 | marketbeat.comUndervalued Penny Stocks To Watch In May 2026May 6, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Is Co-Diagnostics National Security’s Next Diagnostic Pick?By Jeffrey Neal Johnson | May 28, 2026VUZI, GOVX, and CRDL Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.22 -0.06 (-4.69%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$1.25 +0.03 (+2.05%) As of 05/29/2026 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.GeoVax Labs NASDAQ:GOVX$2.06 -0.34 (-14.17%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$2.06 +0.00 (+0.05%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Vuzix NASDAQ:VUZI$4.60 +0.10 (+2.22%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$4.59 -0.01 (-0.22%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vuzix Corporation designs, manufactures, and markets smart glasses and augmented reality (AR) technologies and products for the enterprise, medical, defense, and consumer markets. The company's products include head-mounted smart personal display and wearable computing devices that offer users a portable viewing experience, provide solutions for mobility, wearable displays, and augmented reality, as well as original equipment manufacturer waveguide optical components and display engines. It also provides certified ERP SaaS logistics solution to support hand-held mobile phones and scanners used in logistics, warehousing, and manufacturing applications. It holds approximately 375 patents and patents pending and various IP licenses in the fields of optics, head-mounted displays, and augmented reality Video Eyewear field. It sells its products through resellers, distributors, direct to commercial customers, and online stores, as well as various Vuzix operated web stores in North America, Europe, the Asia-Pacific, and internationally. The company was formerly known as Icuiti Corporation and changed its name to Vuzix Corporation in September 2007. Vuzix Corporation was incorporated in 1997 and is headquartered in West Henrietta, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds These 3 Software Stocks Are Buying Back Shares Hand Over Fist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
